Target Identification for Drug Discovery

Identification of suitable targets is critical for any drug discovery program. However, there is no standardized procedure for target identification in drug discovery. Artificial Intelligence (AI) and machine learning (ML) approaches are increasingly being employed in this process, with the goal of finding clinically effective targets.

BioPrompt has developed an AI-assisted and comprehensive method to identify potential targets by  integrating key factors such as disease relevance, target biology, mechanism of action, pathway analysis, potential toxicity, druggability, potential for  combination therapy, market interest and competitive landscape. This approach results in a curated list of high-value targets, categorized as follows:

Novel Targets: Innovative, unexplored, with high potential.

Fast Follower Targets: Validated targets with limited market competition.

Suitable for:
  • Emerging biotech firms and research Institutions aiming to identify high quality targets for initiating drug development programs.

  • Established companies aiming to expand their pipelines.

Currently Available Targets

Target

Therapeutic Area

Category

BPR-001

Oncology

Immuno-Oncology

BPR-002

BPR-003

A comprehensive project proposal will be available, encompassing disease relevance, target biology, druggability, pathway analysis, hit identification strategies, appropriate screening  assays, flow schemes with Go/No-Go decision points, target product profile (TPP) at various stages, target safety evaluation, a detailed SWOT analysis, competitive landscape and market potential.

Oncology

Oncology

Oncology

Epigenetic Pathway

BPR-004

Epigenetic Pathway

DDR Pathway

Assay Development and Screenig for a Wide Range of Target Classes

  • Kinases

  • Phosphatases

  • GTPases

  • ATPases

  • Helicases

  • Phospho-diesterases

  • Proteases

  • BioPrompt possesses extensive expertise in assay development for a wide range of target types including enzymes, receptors and scaffolding proteins.

  • We offer comprehensive assay development and screening support for these targets.

  • Additional in vitro/ in vivo studies in the preclinical stage can be done through our network of CROs

  • RNA Modifiers

  • Exonucleases

  • Deubiquitinating Enzymes

  • DNA Repair Enzymes

  • Nuclear Receptors

  • GPCRs

  • Epigenetic Targets

Drug Discovery Targets

  • Mitochondrial Chaperones

  • Molecular Motor Proteins

  • E3 Ligases

  • PROTAC/Glue Degrader Targets

  • Immune Checkpoint Proteins

  • Antibodies

  • Scaffolding Proteins

Assay Development with a range of Technologies

  • BioPrompt possesses extensive experience in the development of assays across a broad range of assay technologies.

  • We offer end-to-end support for assay development, screening and data analysis.

  • BioPrompt coordinates assays across a range of technologies through a trusted network of CROs and Institutes.

  • Absorbance

  • Luminescence

  • Fluorescence

  • FRET/TR-FRET

  • Fluorescence Polarization

  • Alpha Screen

  • Surface Plasmon Resonance (SPR)

  • Thermal Shift Assay

  • Biolayer Interferometry (BLI)

  • Microscale Thermophoresis (MST)

  • Nuclear Magnetic Resonance (NMR)

  • Mass Spectrometry

  • Radiometry

  • ELISA

Assay Technologies

Facilitation of Preclinical Studies

  • BioPrompt leverages its CRO partnerships to support the following studies.

  • Different studies can be done at different CROs to optimize cost and service quality.

  • Ideal for startup and small companies lacking the scientific capabilities to perform all studies in-house.

  • Solubility

  • Caco-2/MDCK Permeability

  • Plasma Protein Binding (PPB)

  • Metabolic Stability (m/r/d/h)

  • Hepatocyte Stability

  • Plasma Stability

  • CYP Inhibition

  • Time Dependent Inhibition (TDI)

  • CYP Induction

  • PK Profiling (Mouse/Rat)

  • Maximum Tolerated Dose (MTD)

  • 4/14/28 day Repeated Dose Toxicity

  • hERG Assay

  • Genotoxicity Screening

  • Micronucleus Test

  • Ames Test

  • Single Dose Studies

  • Repeated Dose Studies

  • Dose-Limiting Toxicity Studies

  • Dose Escalation Toxicity Studies

Toxicology Studies

ADME/PK

Expert drug discovery and consulting services for biotech firms and Institutes

© 2025. All rights reserved.

Contact Us Tel: +91 98456 80674 Email: contact@bioprompt.in

Consulting Services Targets for Drug Discovery Facilitation of Preclinical Studies

Location NB-3/44, Vijaya Enclave Bilekahalli, Bangalore - 560076 Karnataka, INDIA

All images are designed by freepik

Our Social Media Profiles